Norfloxacin is a quinolinecarboxylic acid compound. We examined the in vitro activity of this compound against gram-positive and -negative species, including anaerobic species. It inhibited 90% (MIC90) of strains of Escherichia coli at 0.05 pLg/ml, Klebsiella sp. at 0.4 ,ug/ml, Salmonella and Shigella spp. at 0.1 j.g/ml, Citrobacter sp. at 0.4 ,ug/ml, Enterobacter cloacae at 0.2 jig/ml, Enterobacter aerogenes at 0.4 pug/ml, and Enterobacter agglomerans at 0.2 ,ug/ml. The MICs of Proteus mirabilis, Morganella sp., Proteus vulgaris, Proteus rettgeri, and Providencia sp. were 0.1, 0.2, 0.8, 0.3, and 1.6 ,ug/ml, respectively. The MIC90 of Serratia sp. was 1.6 jig/ml, and that of Acinetobacter sp. was 6.3 ,ug/ml. For Pseudomonas aeruginosa the MIC50, the MIC75, and the MIC90 were 0.8, 1.6, and 3.1 Fg/ml, respectively. The MIC50 of Pseudomonas maltophilia was 3.1 ,ug/ml, and the MIC90 was 12.5 p,g/ml. Yersinia, Arizona, and Aeromonas all were inhibited at concentrations below 1 jig/ml, as was Campylobacter. The activity of the compound against gram-positive species was less impressive: the MIC90s of
Streptococcus faecalis were 1.6, 6.3, 3.1, and 12.5 ,ug/ml, respectively. All Listeria strains were inhibited by 3.1 ,g/ml. The activity of norfloxacin was not affected by the type of medium, pH, or inoculum size. There was no major difference between MIC and minimum bactericidal concentration values. Norfloxacin inhibited bacteria in every species which was resistant to ampicillin, carbenicilin, cephalexin, gentamicin, and trimethoprim at concentrations lower than those of aminothiazolyl cephalosporins, moxalactam, and aminoglycosides.
Although a number of antimicrobial agents are available to treat urinary tract, diarrheal, and soft tissue infections due to resistant bacteria, most of these agents must be utilized by the parenteral route. Norfloxacin, an analog of nalidixic acid, is a quinolinecarboxylic acid compound which has been reported to inhibit DNA gyrase activity (personal communication, H. Gadebush, Merck Sharp & Dohme). Preliminary reports of the in vitro activity of the compound were encouraging (1) . For this reason we examined the in vitro activity of this compound against gram-positive and gram-negative species, including anaerobic species which were known to be resistant to many of the currently available antibacterial agents.
MATERIALS AND METHODS
All compounds were obtained from their respective manufacturers. Norfloxacin was obtained from Kyorin Pharmaceuticals. Fresh dilutions of each compound were prepared daily in sterile medium. Bacterial isolates were obtained from patients treated at The Columbia-Presbyterian Medical Center, New York, N.Y. Both recent isolates and isolates multiply resistant to antibiotics which had been saved over the past 5 years were tested. Only one isolate from a patient was tested to avoid multiple copies of the same strain.
Antimicrobial susceptibility tests were measured by an agar dilution method with Mueller-Hinton agar unless otherwise specified. A final inoculum of 10' colony-forming units (CFUs), prepared by dilution of a fresh overnight broth culture, was applied to agar with a replicating spot device. Broth dilutions were performed with 5 x 104 CFUs in tubes of 1-ml volume. Agar plates and tubes were incubated at 35°C for 18 h. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antimicrobial agent that inhibited development of visible growth on agar or in the tubes. The minimal bactericidal concentration (MBC) was determined by plating 0.01 ml from clear tubes to blood agar plates. The MBC was the concentration that inhibited all growth. Anaerobic susceptibility tests were performed with brucella agar supplemented with hemin and vitamin K 
RESULTS
Norfloxacin showed remarkable activity against the majority of the bacteria tested (Table  1) . Ninety percent of strains of Escherichia coli; Klebsiella; Enterobacter; Citrobacter; Proteus mirabilis; Morganella; Salmonella, including S. typhi; Shigella; Arizona; Yersinia; and Campylobacter were inhibited by 0.4 ,ug/ml or less. Among the gram-negative species only a few Providencia, Serratia, and Pseudomonas aeruginosa strains required norfloxacin levels between 1.6 and 6.3 ,ug/ml. Pseudomonas cepacia was susceptible at an MIC9o of 1.6 jj.g/ml, but Pseudomonas maltophilia required levels to 12.5 ,ug/ml. All of the Bacteroidesfragilis strains were inhibited by 12.5 ,ug/ml, and this included strains which had MICs above 50 ,ug/ml for carbenicillin and cefoxitin.
The activity of the compound against streptococcal species was less than its gram-negative activity, but 3.1 ,ug/ml inhibited all Streptococcusfaecalis strains. Oddly, Streptococcus pneumoniae strains were more resistant, with MICs of 12.5 ,ug/ml. Staphylococcus saprophyticus strains, the novobiocin-resistant coagulase-negative staphylococci, were all inhibited by 1.6 ,ug/ ml. All of the Haemophilus and Neisseria strains were inhibited by <0.05 pLg/ml.
The comparative activity of norfloxacin and 1-lactam, aminoglycosides, and trimethoprimsulfamethoxazole is shown in Strains of Serratia sp., which are resistant to Plactams, aminoglycosides, and trimethoprim, were inhibited by 1.6 ,ug of norfloxacin per ml.
These strains, which were resistant to amikacin, were resistant primarily on the basis of permeability, since aminoglycoside-inactivating enzymes for this agent could not be detected. The activity of MK 366 against Providencia sp. was similar to cefotaxime and trimethoprim, but it was superior to these agents against Morganella sp. Norfloxacin inhibited all of the Salmonella strains resistant to ampicillin and the few chloramphenicol-and trimethoprim-resistant isolates. It also inhibited all strains of ampicillin-and tetracycline-resistant Shigella sp. Ampicillin-resistant Haemophilus sp. and Neisseria gonorrhoeae were inhibited by norfloxacin. The compound was active against P. aeruginosa resistant to the newest P-lactams and to tobramycin and amikacin. A number of these strains were not resistant to these other agents due to 3-lactamases or aminoglycoside-modifying enzymes but because of permeability mechanisms. Although the MICs for P. maltophilia and Acinetobacter sp. were higher than for other species, a number of carbenicillin-, cefotaxime-, and moxalactam-resistant isolates were inhibited by 3.1 ,ug/ml. The antibacterial activity of norfloxacin against nalidixic acid-resistant streptococci, staphylococci, Enterobacteriaceae, and Pseudomonas sp. was determined. All Staphylococcus aureus, Streptococcus pyogenes, E. coli, Klebsiella pneumoniae, P. mirabilis, E. cloacae, and P. aeruginosa strains resistant to 2100 ,ug of nalidixic acid per ml were inhibited by <0.8 g of norfloxacin per ml.
The growth medium had a minimal effect on MICs and MBCs. MICs were also determined under anaerobic conditions. For only 3 strains of the 30 tested strains of K. pneumoniae, E. coli, P. mirabilis, E. cloacae, Morganella morganii, and Serratia marcescens was the MIC more than fourfold greater anaerobically than the aerobic MIC. The compound was active at pH 6, 7, and 8 without a major change in MICs.
Inoculum size had only a minor effect on the MICs and MBCs as the inoculum was increased from 103 to i07 CFUs (Table 3 ). In no instance gonorrhoeae (2).
Unlike earlier compounds of this type, resistance to this agent is not easily produced. There is no major difference between inhibitory and lethal action on bacteria, and there do not appear to be members in a population spontaneously resistant to the compound.
Clinical trials to determine its effectiveness in selected infections seem reasonable.
